Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125174 | 0.97 | ALDH1A1 (0.44) | ALDH1A1CYP2C19AKR1C1FFAR3ADORA2A | |
| SCHEMBL2275815 | 0.97 | ALDH1A1 (0.44) | ALDH1A1CYP2C19AKR1C1FFAR3ADORA2A | |
| Hydrochloric Acid SCHEMBL10613912 | 0.95 | ALDH1A1 (0.42) | ALDH1A1CYP2C19AKR1C1ADORA2AADORA1 | |
| SCHEMBL5551595 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL11818558 | 0.92 | ALDH1A1 (0.33) | ALDH1A1FFAR3 | |
| SCHEMBL248308 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL9422815 | 0.86 | — | — | |
| SCHEMBL10854389 | 0.82 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL20068419 | 0.78 | — | — | |
| SCHEMBL1970452 | 0.78 | LMNA (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006956-A9 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024006956-A9 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024006956-A2 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-3571198-B1 | BICYCLIC AMINES AS JAK KINASE INHIBITORS | LEO PHARMA AS (DK) | 2023-02-01 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022133588-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-30 | — | — | WO | disclosed |
| US-20220204476-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-30 | — | — | US | disclosed |
| WO-2022133588-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-30 | — | — | WO | disclosed |
| US-10851116-B2 | Bicyclic amines as novel JAK kinase inhibitors | LEO PHARMA A/S (DK) | 2020-12-01 | — | — | US | disclosed |
| CN-110291090-A | Bentyl as novel jak kinase inhibitor | 利奥制药有限公司 | 2019-09-27 | — | — | CN | disclosed |
| EP-1758891-A2 | BENZIMIDAZOLONE CARBOXYLIC ACID DERIVATIVES | Pfizer Japan Inc. (JP) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123718-A2 | BENZIMIDAZOLONE CARBOXYLIC ACID DERIVATIVES | PFIZER JAPAN INC. (JP) | 2005-12-29 | — | — | WO | disclosed |
| US-20050277671-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER INC | 2005-12-15 | — | — | US | disclosed |
| US-20050277672-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER INC | 2005-12-15 | — | — | US | disclosed |
| US-20050277673-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
| US-4302583-A | BY HEATING THE CORRESPONDING DIMERIC ACYL CYANIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-11-24 | — | — | US | disclosed |
| US-4298748-A | Preparation of 2-imidazolines | BASF AKTIENGESELLSCHAFT (DE) | 1981-11-03 | — | — | US | disclosed |
| US-4196233-A | Process for coating inorganic substrates with carbides, nitrides and/or carbonitrides | CIBA-GEIGY CORPORATION (US) | 1980-04-01 | — | — | US | disclosed |
| US-4028142-A | ON IRON, BORON, SILICON ANDOR GROUP 4B TO 6B METALS BY DECOMPOSITION TO PRODUCE DIFFUSION LAYERS | CIBA-GEIGY CORPORATION (US) | 1977-06-07 | — | — | US | disclosed |
| US-4014889-A | Process for preparing ketones | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204476-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | SARS1, NSUN3, GTF3C4 | ALDH1A1 2958/4885CYP2C19 3729/4885AKR1C1 3778/4885 |
| US-20050277673-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | ALDH1A1 1109/4885CYP2C19 109/4885AKR1C1 1323/4885 |
| US-20050277672-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | ALDH1A1 1109/4885CYP2C19 109/4885AKR1C1 1323/4885 |
| US-10851116-B2 | Bicyclic amines as novel JAK kinase inhibitors | JAK1, JAK2, JAK3 | ALDH1A1 3009/4885CYP2C19 1056/4885AKR1C1 414/4885 |
| US-20050277671-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | ALDH1A1 1109/4885CYP2C19 109/4885AKR1C1 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.